UK Approves Zolbetuximab for Advanced Gastric Cancer Treatment
A New Targeted Cancer Treatment for HER2-Negative Gastric Cancer
What is Zolbetuximab?
Zolbetuximab is a targeted cancer treatment that has been approved in the UK for the treatment of advanced gastric cancer. It is a monoclonal antibody that targets claudin 18.2 (CLDN18.2), a protein that is overexpressed in many gastric cancers. By targeting CLDN18.2, zolbetuximab can block the growth and spread of cancer cells.
Efficacy of Zolbetuximab
Zolbetuximab has been shown to be effective in clinical trials. In a phase 3 trial, patients with advanced gastric cancer who received zolbetuximab in combination with chemotherapy had a significantly improved overall survival compared to those who received chemotherapy alone.
How is Zolbetuximab Given?
Zolbetuximab is given intravenously (IV) every three weeks. The typical dose is 10 mg/kg. Treatment is usually continued until the cancer progresses or the patient experiences unacceptable side effects.
Side Effects of Zolbetuximab
The most common side effects of zolbetuximab include:
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Constipation
- Skin rash
- Itching
- Swelling in the hands and feet
- Weight gain
Conclusion
Zolbetuximab is a new targeted cancer treatment that has been approved in the UK for the treatment of advanced gastric cancer. It is a promising new treatment option for patients with this type of cancer.
Komentar